{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:23:12Z","timestamp":1792185792599,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81401269"],"award-info":[{"award-number":["81401269"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Letrozole can significantly decrease the estrogen level, and has been administrated to prevent the incidence of early ovary hyperstimulation syndrome (OHSS). However, the effect of Letrozole on prevention of OHSS reached to controversial conclusions. The present meta-analysis aim to examine whether Letrozole could reduce the incidence of early OHSS after assisted reproductive technology (ART).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An exhaustive electronic literature search was conducted on MEDLINE, Google Scholar, CNKI and WANFANG MED ONLINE, from inception until May 2018. We include clinical trials that examined the effect of Letrozole on the prevention of early OHSS. The main outcome measures were the incidence of total early OHSS, mild early OHSS, moderate early OHSS, and severe early OHSS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight studies included in the review. Of these, five publications evaluated the effect of Letrozolel on the prevention of total, mild, moderate, and severe OHSS, respectively. The results indicated that there was a significantly decreased incidence of total OHSS with Letrozole compared with control group, and there were no significantly differences in the incidence of mild, moderate, and severe OHSS between study group with Letrozole and control group. Eight studies reported the incidence of moderate\u2009+\u2009severe OHSS. We found a significant decrease in incidence of moderate\u2009+\u2009severe OHSS in high-risk women with Letrozole.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Letrozole has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually; Letrozole should not be considered as the first-line treatment for prevention of OHSS. Further cohort studies are required to explore the effect of Letrozole on the prevention of OHSS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Plain English Summary<\/jats:title>\n                <jats:p>This study aimed to examine whether Letrozole could reduce the incidence of early OHSS after assisted reproductive technology (ART). A meta-analysis including 8 studies was conducted. There were no significantly differences in the incidence of mild, moderate, and severe OHSS between study group with Letrozole and control group. Letrozole has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12978-020-01042-2","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T10:03:44Z","timestamp":1605866624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Jing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"1042_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","volume":"8","author":"A Delvigne","year":"2002","unstructured":"Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559\u201377.","journal-title":"Hum Reprod Update"},{"key":"1042_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/oxfordjournals.humrep.a138598","volume":"9","author":"CA Lyons","year":"1994","unstructured":"Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entitles with different risk factors. Hum Reprod. 1994;9:792\u20139.","journal-title":"Hum Reprod"},{"key":"1042_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0015-0282(00)00670-1","volume":"74","author":"E Geva","year":"2000","unstructured":"Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 2000;74:429\u201338.","journal-title":"Fertil Steril"},{"key":"1042_CR4","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1172\/JCI4814","volume":"102","author":"ER Levin","year":"1998","unstructured":"Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest. 1998;102:1978\u201385.","journal-title":"J Clin Invest"},{"key":"1042_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0015-0282(98)00484-1","volume":"71","author":"A Pellicer","year":"1999","unstructured":"Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1b, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 1999;71:482\u20139.","journal-title":"Fertil Steril"},{"key":"1042_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0015-0282(00)00491-X","volume":"73","author":"JG Whelan","year":"2000","unstructured":"Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:883\u201396.","journal-title":"Fertil Steril"},{"key":"1042_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0015-0282(16)58389-7","volume":"66","author":"A Revel","year":"1996","unstructured":"Revel A, Barak V, Lavy Y, Anteby E, Abramov Y, Schenker JJ, et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril. 1996;66:66\u201371.","journal-title":"Fertil Steril"},{"key":"1042_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0015-0282(97)81436-7","volume":"67","author":"A Delbaere","year":"1997","unstructured":"Delbaere A, Bergmann PJM, Gervy-Decoster C, Deschodt-Lanckman M, de Maertelaer V, Staroukne M, et al. Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Fertil Steril. 1997;67:1038\u201345.","journal-title":"Fertil Steril"},{"key":"1042_CR9","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/HUMREP\/10.6.1355","volume":"10","author":"RS Morris","year":"1995","unstructured":"Morris RS, Wong IL, Kirkman E, Gentschein E, Paulson RJ. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod. 1995;10:1355\u20138.","journal-title":"Hum Reprod"},{"key":"1042_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1749-6632.2011.05983.x","volume":"1221","author":"P Sansone","year":"2011","unstructured":"Sansone P, Aurilio C, Pace MC, Esposito R, Passavanti MB, Pota V, et al. Intensive care treatment of ovarian hyperstimulation syndrome (OHSS). Ann N Y Acad Sci. 2011;1221:109\u201318.","journal-title":"Ann N Y Acad Sci"},{"key":"1042_CR11","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.fertnstert.2008.12.027","volume":"91","author":"H Selman","year":"2009","unstructured":"Selman H, Brusco GF, Fiorini F, Barnocchi N, Mariani M, El-Danasouri I. Vitrification is a highly efficient method to cryopreserve human embryos in in vitro fertilization patients at high risk of developing ovarian hyperstimulation syndrome. Fertil Steril. 2009;91:1611\u20133.","journal-title":"Fertil Steril"},{"key":"1042_CR12","first-page":"158","volume":"44","author":"Z Peng","year":"2019","unstructured":"Peng Z, Liu N. Cumulative live birth rates after frozen embryo transfer and fresh embryo transfer with oocyte numbers more than 15. J Cent South Univ. 2019;44:158\u201363.","journal-title":"J Cent South Univ"},{"key":"1042_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.fertnstert.2007.07.1383","volume":"90","author":"HG Huddleston","year":"2008","unstructured":"Huddleston HG, Racowsky C, Jackson KV, Fox JH, Ginsburg ES. Coasting VS. Cryopreservation of all embryos for prevention of ovarian hyperstimulation syndrome in vitro fertilization. Fertil Steril. 2008;90:1259\u201362.","journal-title":"Fertil Steril"},{"key":"1042_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/humrep\/16.1.24","volume":"16","author":"T Al-Shawaf","year":"2001","unstructured":"Al-Shawaf T, Zosmer A, Hussain S, Tozer A, Panay N, Wilson C, et al. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified \u2018coasting\u2019 strategy based on ultrasound for identification of high-risk patients. Hum Reprod. 2001;16:24\u201330.","journal-title":"Hum Reprod"},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.rbmo.2009.06.001","volume":"19","author":"M Melo","year":"2009","unstructured":"Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online. 2009;19:486\u201392.","journal-title":"Reprod Biomed Online"},{"key":"1042_CR16","first-page":"186","volume":"24","author":"XY Lu","year":"2004","unstructured":"Lu XY, Li YP. Application of gonadotropin releasing hormone antagonist in ART. Reproductive Contraeption. 2004;24:186\u201390.","journal-title":"Reproductive Contraeption"},{"key":"1042_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0015-0282(01)01784-8","volume":"75","author":"Y Abramov","year":"2001","unstructured":"Abramov Y, Fatum M, Abrahamov D, Schenker JG. Hydroxyethyl starch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril. 2001;75:1228\u201330.","journal-title":"Fertil Steril"},{"key":"1042_CR18","first-page":"102","volume":"21","author":"F Gong","year":"2012","unstructured":"Gong F, Cai SF, Lin G, Zhang SJ, Li J, Lu GX. New strategy to prevent OHSS in PCOS patients receiving IVF treatment. J Reprod Med. 2012;21:102\u20136.","journal-title":"J Reprod Med"},{"key":"1042_CR19","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/HUMREP\/10.6.1373","volume":"10","author":"E Shalev","year":"1995","unstructured":"Shalev E, Giladi Y, Matilsky M, Ben-Ami M. Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study. Hum Reprod. 1995;10:1373\u20136.","journal-title":"Hum Reprod"},{"key":"1042_CR20","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.fertnstert.2009.01.085","volume":"93","author":"A Varnagy","year":"2010","unstructured":"Varnagy A, Bodis J, Manfai Z, Wilhelm F, Busznyak C, Koppan M. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril. 2010;93:2281\u20134.","journal-title":"Fertil Steril"},{"key":"1042_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.fertnstert.2008.01.077","volume":"89","author":"A Varnagy","year":"2008","unstructured":"Varnagy A, Koppan M, Manfai Z, Busznyak C, Bodis J. Low-dose aspirin for prophylaxis of ovarian hyperstimulation syndrome. Fertil Steril. 2008;89:1035\u20136.","journal-title":"Fertil Steril"},{"key":"1042_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","volume":"17","author":"C Carizza","year":"2008","unstructured":"Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online. 2008;17:751\u20135.","journal-title":"Reprod Biomed Online"},{"key":"1042_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.fertnstert.2011.04.094","volume":"96","author":"T Gurgan","year":"2011","unstructured":"Gurgan T, Demirol A, Guven S, Benkhalifa M, Girgin B, Li TC. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril. 2011;96:53\u20137.","journal-title":"Fertil Steril"},{"key":"1042_CR24","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.fertnstert.2011.09.020","volume":"96","author":"S Palomba","year":"2011","unstructured":"Palomba S, Falbo A, Carrillo L, Villani MT, Orio F, Russo T, et al. MET-formin in High Responder Italian Group. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin- stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril. 2011;96:1384\u201390.","journal-title":"Fertil Steril"},{"key":"1042_CR25","first-page":"720","volume":"37","author":"F Gong","year":"2012","unstructured":"Gong F, Guo H, Shen Y, Li J, Lu G, Lin G. Reproductive analysis of treatment for severe ovary hyperstimulation syndrome complicated by pleural effusion and ascites. J Cent South Univ. 2012;37:720\u20134.","journal-title":"J Cent South Univ"},{"key":"1042_CR26","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/humrep\/deg208","volume":"18","author":"M Aboulghar","year":"2003","unstructured":"Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. Hum Reprod. 2003;18:1140\u20131.","journal-title":"Hum Reprod"},{"key":"1042_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.fertnstert.2005.01.117","volume":"84","author":"JA Garcia-Velasco","year":"2005","unstructured":"Garcia-Velasco JA, Moreno L, Pacheco A, Guillen A, Duque L, Requena A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril. 2005;84:82\u20137.","journal-title":"Fertil Steril"},{"key":"1042_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.fertnstert.2008.04.042","volume":"92","author":"JA Garcia-Velasco","year":"2009","unstructured":"Garcia-Velasco JA, Quea G, Piro M, Mayoral M, Ruiz M, Toribio M, et al. Letrozole administration druing the luteal phase after ovarian stimulation impacts corpus luteal function: A randomized, placebo-controlled trial. Fertil Steril. 2009;92:222\u20135.","journal-title":"Fertil Steril"},{"key":"1042_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1472-6483(10)60212-X","volume":"17","author":"HM Fatemi","year":"2008","unstructured":"Fatemi HM, Popovic-Todorovic B, Donoso P, Papanikolaou E, Smitz J, Devroey P. Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. Reprod Biomed Online. 2008;17:307\u201311.","journal-title":"Reprod Biomed Online"},{"issue":"42","key":"1042_CR30","first-page":"e1","volume":"216","author":"QY Mai","year":"2017","unstructured":"Mai QY, Hu XK, Yang G, Luo YY, Huang KJ, Yuan Y, Zhou CQ. Effect of letrozole on moderate and severe early \u2013onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial. Am J Obstet Gynecol. 2017;216(42):e1-10.","journal-title":"Am J Obstet Gynecol"},{"key":"1042_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3109\/19396368.2014.957879","volume":"60","author":"QH He","year":"2014","unstructured":"He QH, Liang LL, Zhang CL, Li HS, Ge ZJ, Wang L, et al. Effects of different doses of letrozole on the incidence of early \u2013onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med. 2014;60:355\u201360.","journal-title":"Syst Biol Reprod Med"},{"key":"1042_CR32","first-page":"909","volume":"49","author":"QH He","year":"2014","unstructured":"He QH, Xu JN, Cui SH, Li HS, Zhang CL. Relationship between letrozole administration during the luteal phase after oocyte retrieval and the early-stage ovarian hyperstimulation syndrome occurrence. Chin J Obstet Gynecol. 2014;49:909\u201313.","journal-title":"Chin J Obstet Gynecol"},{"key":"1042_CR33","unstructured":"Yu ZJ. The clinical research of letrozole on the treatment of ovarian hyperstimulation syndrome. Master\u2019s thesis of Anhui Medical University. 2017."},{"key":"1042_CR34","first-page":"363","volume":"33","author":"L Zhang","year":"2017","unstructured":"Zhang L, Li P, Lin J, He XM, Shi YY, Ye YP, et al. Clinical effect analysis of letrozole on preventing ovarian hyperstimulation after oocyte retrieval. J Practical Obstet Gynecol. 2017;33:363\u20135.","journal-title":"J Practical Obstet Gynecol"},{"key":"1042_CR35","first-page":"869","volume":"35","author":"YQ Wang","year":"2013","unstructured":"Wang YQ, Yang J, Xu WM, Xie QZ, Yan WJ, Yin TL, et al. Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome. J Peking Univ. 2013;35:869\u201372.","journal-title":"J Peking Univ"},{"key":"1042_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13048-015-0190-y","volume":"8","author":"YQ Wang","year":"2015","unstructured":"Wang YQ, Luo J, Xu WM, Xie QZ, Yan WJ, Wu GX, et al. Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS? J Ovarian Res. 2015;8:63.","journal-title":"J Ovarian Res"},{"key":"1042_CR37","first-page":"117","volume":"31","author":"J Lin","year":"2016","unstructured":"Lin J, Li P, Sha YW, Shi YY, Deng BB, Ye YP. Prevention of ovary hyperstimulation syndrome using letrozole after oocyte retrieval. Matern Child Health Care China. 2016;31:117\u20138.","journal-title":"Matern Child Health Care China"},{"key":"1042_CR38","unstructured":"Wells G, SBOD. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of non-randomised Studies in meta-analysis. In: Proceedings or the Third Symposium on Systematic Reviews beyond the Basics. Improving Quality and Impact, Oxford, 3\u20135 July 2000."},{"key":"1042_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","volume":"44","author":"A Golan","year":"1989","unstructured":"Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430\u201340.","journal-title":"Obstet Gynecol Surv"},{"key":"1042_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0015-0282(16)55188-7","volume":"58","author":"D Navot","year":"1992","unstructured":"Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249\u201361.","journal-title":"Fertil Steril"},{"key":"1042_CR41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/molehr\/gar047","volume":"17","author":"K Jarkovska","year":"2011","unstructured":"Jarkovska K, Kupcova Skalnikova H, Halada P, Hrabakova R, Moos J, Rezabek K, et al. Development of ovarian hyperstimulation syndrome: interrogation of key proteins and biological processes in human follicular fluid of women undergoing in vitro fertilization. Mol Hum Reprod. 2011;17:679\u201392.","journal-title":"Mol Hum Reprod"},{"key":"1042_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.fertnstert.2011.12.046","volume":"97","author":"SR Soares","year":"2012","unstructured":"Soares SR. Etiology of OHSS and use of dopamine agonists. Fertil Steril. 2012;97:517\u201322.","journal-title":"Fertil Steril"},{"key":"1042_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1472-6483(10)60040-5","volume":"19","author":"A Delvigne","year":"2009","unstructured":"Delvigne A. Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS Reprod Biomed Online. 2009;19:8\u201313.","journal-title":"Epidemiology of OHSS Reprod Biomed Online"},{"key":"1042_CR44","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/oxfordjournals.humrep.a137276","volume":"6","author":"RH Asch","year":"1991","unstructured":"Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk group. Hum Reprod. 1991;6:1395\u20139.","journal-title":"Hum Reprod"},{"key":"1042_CR45","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1055\/s-0030-1265675","volume":"28","author":"R Abdallah","year":"2010","unstructured":"Abdallah R, Kligman I, Davis O, Rosenwaks Z. Withholding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med. 2010;28:486\u201392.","journal-title":"Semin Reprod Med"},{"key":"1042_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1477-7827-9-85","volume":"9","author":"EG Papanikolaou","year":"2011","unstructured":"Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H, et al. Aromatase inhibitors in stimulated IVF cycles. Reprod Biod Endocrinol. 2011;9:85.","journal-title":"Reprod Biod Endocrinol"},{"key":"1042_CR47","unstructured":"Li YP, Zhang Q, Zhou QE, Liu DE, Liu NH, Deng L, Chen XH. Clinical study on letrozole for induction of ovulation."},{"key":"1042_CR48","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","volume":"106","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2016","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106:1634\u201347.","journal-title":"Fertil Steril"},{"key":"1042_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0015-0282(98)00447-6","volume":"71","author":"R Agrawal","year":"1999","unstructured":"Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril. 1999;71:287\u201393.","journal-title":"Fertil Steril"},{"key":"1042_CR50","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0015-0282(97)81908-5","volume":"67","author":"Y Abramov","year":"1997","unstructured":"Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril. 1997;67:261\u20135.","journal-title":"Fertil Steril"}],"container-title":["Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-020-01042-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12978-020-01042-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-020-01042-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T10:06:06Z","timestamp":1605866766000},"score":1,"resource":{"primary":{"URL":"https:\/\/reproductive-health-journal.biomedcentral.com\/articles\/10.1186\/s12978-020-01042-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1186\/s12978-020-01042-2","relation":{},"ISSN":["1742-4755"],"issn-type":[{"value":"1742-4755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"1 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}